This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: P355 Preferences and satisfaction of IBD patients in whom the adalimumab regimen was changed from 40 mg weekly to 80 mg every other week: the ADASCAL study, Journal of Crohn s and Colitis, May 2021, Oxford University Press (OUP),
DOI: 10.1093/ecco-jcc/jjab076.479.
You can read the full text:
The following have contributed to this page
